Jesper Lerche Jakobsen

QA Manager at Symphogen

Jesper Lerche Jakobsen has a diverse work experience spanning multiple industries. Jesper Lerche is currently working as a QA Specialist at Symphogen since June 2021. Prior to that, they worked as a QA Professional at AJ Vaccines from January 2017 to May 2021. Jesper Lerche gained valuable experience at Statens Serum Institut, where they served as a Quality Assurance Compliance Unit member from August 2016 to January 2017 and as a Quality Control Scientist from June 2013 to July 2016. Jesper also worked as a Staff Employee at Tivoli from April 2012 to June 2013. Before that, they were a Scientist at Bavarian Nordic A/S, where they contributed to various projects including the purchase of equipment for the QC laboratory and evaluation of raw materials in smallpox vaccine production, from April 2010 to July 2011. Earlier in their career, Jesper worked as a Sales Assistant at Shell from October 2002 to January 2006. Jesper Lerche also served as a Konstabel i Den Internationale Brigade in Forsvaret from February 1999 to January 2006 and worked as a Postbud at Post Danmark from June 2001 to January 2002.

Jesper Lerche Jakobsen completed their Master's degree in Biotechnology from DTU - Technical University of Denmark. Jesper Lerche pursued this degree from 2000 to 2007. In addition, they have acquired a certification as a Lead auditor from Pharmakon in June 2020. Moreover, they hold a Prince2 Foundation certification, but the institution and specific date of acquisition are unspecified.

Location

Hvidovre, Denmark

Links

Previous companies


Org chart

This person is not in the org chart


Teams


Offices


Symphogen

3 followers

Symphogen is a clinical-stage antibody oncology focused company with a differentiated product pipeline and significant commercial opportunities. Inspired by nature, led by science and driven by people, we passionately strive to make that discovery that may have great effect on the lives of patients, their families, and their caregivers. Based on our monoclonal antibody (mAb) research platform, we create differentiated mAb and mAb mixture products candidates. Our pre-clinical and clinical pipeline is well suited for a precision-medicine approach by addressing well-defined, biomarker-selected patient populations. We are headquartered in Denmark with operations in the US.


Industries

Headquarters

Ballerup, Denmark

Employees

51-200

Links